Diversity In Clinical Trials Velocity Clinical Research

Diversity In Clinical Trials Velocity Clinical Research The company partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, and diagnostics that could improve human health and wellbeing. velocity's unified research site solutions deliver the right patients, investigators, and research staff for phase 1 4 clinical trials across the u.s. and europe. This highlights the importance of diversity, not only in the participant population, but also in the clinical research workforce. building trust and engagement with patients is key to increasing clinical trial recruitment, participation, and completion rates. to do so, velocity invests in diversity, equity, and inclusion (dei) initiatives that.

Velocity Collaborates With Merck To Improve Diversity In Clinical The velocity team had the honor of hosting former u.s. surgeon general and chairman of the board of total diversity clinical trial management, jerome adams, md, mph.he joined an internal call to discuss the importance of diversity in clinical research, highlighting the need for diverse patient populations in clinical trials to ensure new treatments are safe and effective. Velocity recently asked some key employees to come together and discuss a wide array of issues impacting diversity, equity, and inclusion (dei) in clinical trials. velocity’s ongoing goals are to share best practices, identify and address shortcomings, and bring as many perspectives and viewpoints to the table as possible to advance clinical. September 19, 2024. achieving diversity, equity, and inclusion (dei) in clinical trials is crucial for producing comprehensive and effective medical research benefitting all communities. dei ensures clinical research encompasses diverse populations, considering variations in gender, race, ethnicity, socioeconomic status, and more. Broadly, the goals of increasing diversity in clinical trial participation include earning and building trust, promoting fairness, and generating biomedical knowledge (see table). these three.